Weddell R.A., Weiser R.
Department of Surgical Neurology and Clinical Neuropsychology, Morriston Hospital Swansea; and Psychology Department, University College of Swansea, Swansea, UK.
Behav Pharmacol. 1995 Jan;6(1):81-91.
The effects of bromocriptine on potentially dissociable functions were investigated in this double-blind placebo-controlled trial in previously untreated Parkinsonian patients. Bromocriptine-induced reductions in response time were independent of variations in the complexity of the cognitive or motor programming components of reaction time tasks. These results suggest that bromocriptime speeds up response initiation, and it may also improve some "early" visual processes. No clear-cut verbal memory, visuospatial or general intellectual changes were produced by bromocriptine; however, further evaluation of the effects of bromocriptine on "executive" cognitive functions is clearly required. Psychiatric distress was significantly reduced when the active drug was administered. While mood improvements could not be statistically dissociated from motor improvements, review of the literature suggested that decreased emotional distress may have arisen through bromocriptine's action on neural circuits modulating mood. Some clinical implications of bromocriptine's effect on mood are mentioned.
在这项针对既往未接受治疗的帕金森病患者的双盲安慰剂对照试验中，研究了溴隐亭对潜在可分离功能的影响。溴隐亭引起的反应时间缩短与反应时间任务的认知或运动编程成分的复杂性变化无关。这些结果表明，溴隐亭可加快反应启动，还可能改善一些“早期”视觉过程。溴隐亭未产生明显的言语记忆、视觉空间或一般智力变化；然而，显然需要进一步评估溴隐亭对“执行”认知功能的影响。服用活性药物时，精神困扰显著减轻。虽然情绪改善在统计学上与运动改善无法区分，但文献综述表明，情绪困扰的减轻可能是由于溴隐亭对调节情绪的神经回路的作用。文中提到了溴隐亭对情绪影响的一些临床意义。
